secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001140361-24-005889
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anne Johnson named CFO of atai Life Sciences; Stephen Bardin departs
--------------------------------------------------------------------

- Stephen Bardin steps down as CFO effective Feb 6, 2024; will advise through March 31, 2024.
- Anne Johnson, previously Interim CFO and Chief Accounting Officer, appointed CFO.
- Bardin receives severance: 9 months base salary, COBRA, $149,600 bonus, $30,462 parental leave.
- Johnson brings ~20 years biopharma experience from Aruvant, Chimerix, PPD, and Xanodyne.
- Separation agreement includes release of claims and non-disclosure covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/ef20020799_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-005889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer